Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Synta’s Ganetespib Could Break The Hsp90i Curse

This article was originally published in The Pink Sheet Daily

Executive Summary

If ganetespib succeeds in Phase III, it could become the first new treatment for advanced lung adenocarcinoma in a decade, but the heat shock protein class has yet to produce a winner.

You may also be interested in...



Synta’s Newest Phase II Results Could Reshape Ganetespib’s Pivotal Data, But Some Remain Skeptical

Synta provided one-year follow-up data for its Phase IIb/III trial testing ganetespib in NSCLC and revealed some protocol changes which it believes will de-risk the Phase III design. Analysts on the third quarter earnings call by and large bought into the story, but some skepticism remains.

Synta’s Newest Phase II Results Could Reshape Ganetespib’s Pivotal Data, But Some Analysts Remain Skeptical

Synta provided one-year follow up data for its Phase IIb/III trial testing ganetespib in NSCLC, and revealed some protocol changes which it believes will de-risk the Phase III design. Analysts on the third quarter earnings call by and large bought into the story, but some skepticism remains.

New Drugs Build On Personalized Medicine Momentum In Lung Cancer

Crop of new treatments with data at the European Society of Medical Oncology meeting includes second-generation inhibitors of ALK and heat shock protein 90.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1134882

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel